Potential CAR-T treatment centers announced (England)

Thank you to my NHS England Cancer Pharmacist colleagues for sharing the Information on the ‘potential’ treatment sites for delivery of CAR-T therapy in England.  As yet we are unaware of potential sites in the rest of the home nations, so would be grateful if BOPA members can share any relevant information on this exciting new cancer treatment via our forums or via email to [email protected] so we can share

NHS England is pleased to confirm that the following 8 centres have been selected for the first JACIE inspections for accreditation in delivering Immune Effector Cell therapy, based on their submissions, geographical access and advice from JACIE and industry partners:
 
•         Great Ormond Street Hospital NHS Foundation Trust     
•         King’s College Hospital NHS Foundation Trust     
•         Manchester University Hospitals NHS Foundation Trust (MRI /Royal Manchester Children’s Hospital)     
•         The Christie NHS Foundation Trust
•         The Newcastle Upon Tyne Hospitals NHS Foundation Trust         
•         University College London Hospitals NHS Foundation Trust
•         University Hospitals Birmingham NHS Foundation Trust                
•         University Hospitals Bristol NHS Foundation Trust
 
Further instructions are being sent to the sites identified for inspection.
 
This is the first phase of a national implementation of CAR T cell therapy with further phases expected in due course.
 
 

Latest News

By UK SACT Protocols Pilot Team on 20th November 2026

Have Your Say: Review the First UK SACT Protocol and Provide Feedback

Dear Colleagues working in cancer services We are writing to invite you to review and provide feedback on the first protocol produced as part of the UK SACT Protocols Pilot.…

Read article
By Mohammed Patel on 11th November 2026

UK BMT Pharmacists Group Educational Meeting – Friday 13th November 2026. Time:14:00 to 16:00

The next UK BMT Pharmacists Group Educational Meeting is on Friday 13th November, 2pm–4pm. The sessions include: Maintenance Therapy for AML After Allogeneic BMT with Dr Mili Shah, Consultant Haematologist,…

Read article
By UK SACT Board on 9th November 2026

New UK SACT Board National Intrathecal and Intraventricular SACT Guidance

Dear colleagues, We are pleased to share the newly published UK SACT Board National Guidance on the Safe Administration of Systemic Anti-Cancer Therapies via the Intrathecal or Intraventricular Routes. This…

Read article
By BOPA Executive Committee on 9th November 2026

BOPA members flying the flag for cancer pharmacy at ESMO 2026

It was fantastic to see BOPA members representing cancer pharmacy at ESMO Congress 2026 in Madrid, which brought together the global cancer community from 23 to 27 October to share…

Read article